BR112022023591A2 - Proteína spike (s) do coronavírus modificada e métodos de uso da mesma - Google Patents
Proteína spike (s) do coronavírus modificada e métodos de uso da mesmaInfo
- Publication number
- BR112022023591A2 BR112022023591A2 BR112022023591A BR112022023591A BR112022023591A2 BR 112022023591 A2 BR112022023591 A2 BR 112022023591A2 BR 112022023591 A BR112022023591 A BR 112022023591A BR 112022023591 A BR112022023591 A BR 112022023591A BR 112022023591 A2 BR112022023591 A2 BR 112022023591A2
- Authority
- BR
- Brazil
- Prior art keywords
- modified
- methods
- protein
- proteins
- coronavirus spike
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 102100031673 Corneodesmosin Human genes 0.000 abstract 2
- 101710139375 Corneodesmosin Proteins 0.000 abstract 2
- 241000711573 Coronaviridae Species 0.000 abstract 1
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108091005573 modified proteins Proteins 0.000 abstract 1
- 102000035118 modified proteins Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063032502P | 2020-05-29 | 2020-05-29 | |
| PCT/US2021/034713 WO2021243122A2 (en) | 2020-05-29 | 2021-05-28 | Engineered coronavirus spike (s) protein and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022023591A2 true BR112022023591A2 (pt) | 2022-12-27 |
Family
ID=78722816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022023591A BR112022023591A2 (pt) | 2020-05-29 | 2021-05-28 | Proteína spike (s) do coronavírus modificada e métodos de uso da mesma |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4157345A4 (https=) |
| JP (1) | JP2023527556A (https=) |
| KR (1) | KR20230018394A (https=) |
| CN (1) | CN116802193A (https=) |
| AU (1) | AU2021279079A1 (https=) |
| BR (1) | BR112022023591A2 (https=) |
| CA (1) | CA3180554A1 (https=) |
| IL (1) | IL298131A (https=) |
| MX (1) | MX2022015040A (https=) |
| WO (1) | WO2021243122A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012323782B2 (en) | 2011-10-12 | 2017-04-06 | Vaxxas Pty Limited | Delivery device |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| WO2021229270A1 (es) | 2020-05-13 | 2021-11-18 | Laboratorio Avi-Mex, S.A. De C.V. | Vacuna recombinante contra covid-19 en vector viral |
| WO2021249011A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Hiv vaccine compositions, methods, and uses thereof |
| WO2021249116A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Coronavirus vaccine compositions, methods, and uses thereof |
| WO2022041760A1 (en) | 2020-08-31 | 2022-03-03 | Sichuan Clover Biopharmaceuticals, Inc. | Methods and compositions for purification of trimeric fusion proteins |
| US11918643B2 (en) | 2020-12-22 | 2024-03-05 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
| WO2023067193A2 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Compositions for administration of different doses of rna |
| US20250122546A1 (en) | 2021-10-28 | 2025-04-17 | BioNTech SE | Rna constructs and uses thereof |
| AU2022398292A1 (en) | 2021-11-29 | 2024-06-13 | BioNTech SE | Coronavirus vaccine |
| WO2023147091A1 (en) | 2022-01-28 | 2023-08-03 | BioNTech SE | Coronavirus vaccine |
| WO2023196634A2 (en) * | 2022-04-08 | 2023-10-12 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| WO2024086575A1 (en) | 2022-10-17 | 2024-04-25 | BioNTech SE | Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection |
| EP4608442A1 (en) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
| EP4670167A1 (en) | 2023-02-24 | 2025-12-31 | BioNTech SE | Systems and methods for modifying synthetic antigens to promote personalized immune responses |
| EP4669348A1 (en) | 2023-02-24 | 2025-12-31 | BioNTech SE | IMMUNOGENEOUS COMPOSITIONS |
| WO2024243641A1 (en) * | 2023-06-02 | 2024-12-05 | Vaxxas Pty Limited | Covid vaccine delivered by hd-map |
| WO2024249848A2 (en) * | 2023-06-02 | 2024-12-05 | The Scripps Research Institute | Coronavirus s2 immunogens |
| WO2025106754A1 (en) | 2023-11-15 | 2025-05-22 | BioNTech SE | Coronavirus vaccine |
| FR3155424A1 (fr) | 2023-11-15 | 2025-05-23 | BioNTech SE | Compositions immunogènes contre le sars-cov-2 |
| WO2025179238A2 (en) | 2024-02-23 | 2025-08-28 | BioNTech SE | Coronavirus vaccine |
| WO2026047603A1 (en) | 2024-08-28 | 2026-03-05 | BioNTech SE | Sars-cov-2 immunogenic compositions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2970398B1 (en) * | 2013-03-13 | 2024-05-08 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Prefusion rsv f proteins and their use |
| US10538557B2 (en) * | 2015-09-02 | 2020-01-21 | Janssen Vaccines & Prevention B.V. | Stabilized viral class I fusion proteins |
| US10960070B2 (en) * | 2016-10-25 | 2021-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
| US11890339B2 (en) * | 2018-08-03 | 2024-02-06 | The United States of Americam as represented by the Secretary, Department of Health and Human Services | Nipah virus immunogens and their use |
| CN111088283B (zh) * | 2020-03-20 | 2020-06-23 | 苏州奥特铭医药科技有限公司 | mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 |
-
2021
- 2021-05-28 WO PCT/US2021/034713 patent/WO2021243122A2/en not_active Ceased
- 2021-05-28 AU AU2021279079A patent/AU2021279079A1/en active Pending
- 2021-05-28 KR KR1020227042842A patent/KR20230018394A/ko active Pending
- 2021-05-28 CA CA3180554A patent/CA3180554A1/en active Pending
- 2021-05-28 IL IL298131A patent/IL298131A/en unknown
- 2021-05-28 BR BR112022023591A patent/BR112022023591A2/pt unknown
- 2021-05-28 EP EP21811955.0A patent/EP4157345A4/en active Pending
- 2021-05-28 MX MX2022015040A patent/MX2022015040A/es unknown
- 2021-05-28 JP JP2022573585A patent/JP2023527556A/ja active Pending
- 2021-05-28 CN CN202180049973.2A patent/CN116802193A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230018394A (ko) | 2023-02-07 |
| JP2023527556A (ja) | 2023-06-29 |
| IL298131A (en) | 2023-01-01 |
| AU2021279079A1 (en) | 2022-12-15 |
| CN116802193A (zh) | 2023-09-22 |
| EP4157345A2 (en) | 2023-04-05 |
| CA3180554A1 (en) | 2021-12-02 |
| WO2021243122A3 (en) | 2022-02-10 |
| WO2021243122A2 (en) | 2021-12-02 |
| EP4157345A4 (en) | 2024-09-11 |
| US20230242594A1 (en) | 2023-08-03 |
| MX2022015040A (es) | 2023-02-27 |
| WO2021243122A8 (en) | 2022-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022023591A2 (pt) | Proteína spike (s) do coronavírus modificada e métodos de uso da mesma | |
| MX2023004078A (es) | Proteinas f de hmpv estabilizadas por prefusion. | |
| BR112017025108A2 (pt) | compostos seletivos de pyy e usos dos mesmos | |
| BR112022011177A2 (pt) | Domínios de repetição de anquirina projetados com resíduos de superfície alterados | |
| AR066395A1 (es) | Reovirus que tienen secuencias modificadas | |
| BRPI1013780B8 (pt) | Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica | |
| BR112015022191A2 (pt) | compostos heteroarila, seu uso e composição que os compreende | |
| BR112016023979A2 (pt) | métodos de melhora ou aceleração da recuperação física após cirurgia para fratura óssea | |
| ECSP066794A (es) | Nuevos compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c | |
| BRPI0715396B8 (pt) | método de produção de uma composição para vacina | |
| DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
| BR112023002951A2 (pt) | Compostos de fosfolipídio e usos destes | |
| ECSP066792A (es) | Cetoamidas novedosas con p4 cíclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c | |
| BRPI0807487A8 (pt) | Uso de antagonistas de il-23 para o tratamento de infecção | |
| MX391136B (es) | FRAGMENTOS DE OspA ESTABILIZADOS CON CISTEÍNA Y MÉTODO DE USO | |
| BR112015012366A8 (pt) | antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido | |
| NO20064584L (no) | Tetrahydropyridoindolderivater | |
| BR112019001253A2 (pt) | composto, composição farmacêutica, e, métodos de tratamento de câncer ou de atrofia muscular e de doença de parkinson. | |
| BR112014002817A2 (pt) | Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62 | |
| BR112015009280A2 (pt) | preparações liofilizadas de melfalana flufenamida | |
| BR112022022859A2 (pt) | Vacinas contra sars-cov-2 | |
| BR112023019301A2 (pt) | Formulações de vacina de coronavírus | |
| BR112021024651A2 (pt) | Composição farmacêutica parenteral isotônica, método para melhoria da estabilidade química da dita composição e uso de manitol ou um sal | |
| BR112014012726A8 (pt) | composições de cuidado dos cabelos | |
| BR112016002354A2 (pt) | composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit |